← Eichor
Condition: Choroidal Neovascularization Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Choroidal Neovascularization

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MMP-9 Inhibition for Recalcitrant Wet AMD
Phase 2 · 1 location(s) · University of Iowa · NCT04504123Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Va
Phase 4 · 31 location(s) · Association for Innovation and Biomedical Research on Light · NCT06709339A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Phase 2/Phase 3 · 91 location(s) · EyeBiotech Ltd. · NCT07440225Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal
Phase 3 · 1 location(s) · Yeungnam University College of Medicine · NCT07461441Effect of Video Viewing on Intravitreal Injection Experience
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07002372Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive P
Phase 3 · 1 location(s) · Yeungnam University College of Medicine · NCT07389980Biomarkers and Choroidal Neovascularization
Phase N/A · 2 location(s) · Institut National de la Santé Et de la Recherche Médicale, F · NCT04439708OCT in Rare Chorioretinal Diseases
Phase N/A · 1 location(s) · Oregon Health and Science University · NCT02141308A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histo
Phase 4 · 2 location(s) · Cincinnati Eye Institute, Southwest Ohio · NCT07695298Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Phase 3 · 181 location(s) · AbbVie · NCT05407636A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Phase 2/Phase 3 · 63 location(s) · EyeBiotech Ltd. · NCT07496567AVIGA3 (Cohort 2.0)
NA · 1 location(s) · Tan Tock Seng Hospital · NCT07255859Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
Phase 4 · 1 location(s) · Hospital Authority, Hong Kong · NCT06742307
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.